Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:alsoKnownAs |
Breast Cancer Prevention Trial
|
| gptkbp:clinicalTrialPhase |
NCT00002864
|
| gptkbp:controls |
placebo
|
| gptkbp:endDate |
1997
|
| gptkbp:fullName |
National Surgical Adjuvant Breast and Bowel Project Protocol P-1
|
| https://www.w3.org/2000/01/rdf-schema#label |
NSABP P-1 trial
|
| gptkbp:intervention |
gptkb:tamoxifen
|
| gptkbp:location |
gptkb:United_States
|
| gptkbp:participants |
13388
|
| gptkbp:population |
women at increased risk for breast cancer
|
| gptkbp:principalInvestigator |
gptkb:Bernard_Fisher
|
| gptkbp:publishedIn |
Fisher B, et al. J Natl Cancer Inst. 1998;90(18):1371-1388.
|
| gptkbp:result |
incidence of invasive breast cancer
tamoxifen reduced risk of breast cancer by about 50% |
| gptkbp:sideEffect |
increased risk of endometrial cancer
increased risk of thromboembolic events |
| gptkbp:sponsor |
gptkb:National_Cancer_Institute
|
| gptkbp:startDate |
1992
|
| gptkbp:studyType |
gptkb:clinical_trial
|
| gptkbp:bfsParent |
gptkb:Victor_G_Vogel_III
|
| gptkbp:bfsLayer |
7
|